Exelixis (EXEL) Stock Forecast & Price Target $39.25 +0.04 (+0.10%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$39.26 +0.01 (+0.01%) As of 10/17/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Exelixis - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 24 Analyst RatingsSell0Hold9Buy15 Based on 24 Wall Street analysts who have issued ratings for Exelixis in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 9 have given a hold rating, and 15 have given a buy rating for EXEL. Consensus Price Target $44.4213.17% Upside According to the 24 analysts' twelve-month price targets for Exelixis, the average price target is $44.42. The highest price target for EXEL is $60.00, while the lowest price target for EXEL is $33.00. The average price target represents a forecasted upside of 13.17% from the current price of $39.25. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for EXEL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Exelixis and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXEL Analyst Ratings Over TimeTypeCurrent Forecast10/18/24 to 10/18/251 Month Ago9/18/24 to 9/18/253 Months Ago7/20/24 to 7/20/251 Year Ago10/19/23 to 10/18/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy15 Buy rating(s)14 Buy rating(s)12 Buy rating(s)10 Buy rating(s)Hold9 Hold rating(s)9 Hold rating(s)8 Hold rating(s)5 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$44.42$44.42$45.28$29.07Forecasted Upside13.17% Upside9.82% Upside1.82% Upside0.59% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy EXEL Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History EXEL Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Exelixis Stock vs. The CompetitionTypeExelixisMedical CompaniesS&P 500Consensus Rating Score 2.63 2.33 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside13.17% Upside1,356.27% Upside13.60% UpsideNews Sentiment RatingPositive NewsSee Recent EXEL NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/8/2025Weiss Ratings0 of 5 stars Reiterated RatingBuy (B)9/17/2025Morgan Stanley3 of 5 starsSean Laaman Not RatedBoost TargetOverweight$46.00 ➝ $50.00+23.33%9/17/2025The Goldman Sachs Group3 of 5 starsPaul Choi Not RatedInitiated CoverageSell ➝ Buy$47.00+20.08%9/17/2025BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEtzer DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageEqual Weight$40.00+2.20%8/26/2025Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold8/12/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRobert BurnsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$53.00 ➝ $46.00+22.96%7/30/2025UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAshwani VermaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetNeutral$43.00 ➝ $38.00+1.06%7/29/2025Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAsthika GoonewardeneSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$56.00 ➝ $49.00+31.64%7/29/2025William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform7/29/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLeonid TimashevSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSector Perform$50.00 ➝ $45.00+20.97% Get the Latest News and Ratings for EXEL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. 7/29/2025GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael SchmitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$45.00+19.71%7/29/2025JMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSilvan TuerkcanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingMarket Outperform$50.00+33.01%7/29/2025Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingStephen WilleySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetHold$38.00 ➝ $41.00-7.64%6/24/2025Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set TargetBuy$50.00+14.86%6/24/2025StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSudan LoganathanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$29.00 ➝ $60.00+38.34%6/23/2025BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingNeutral6/5/2025Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJason GerberrySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$45.00 ➝ $46.00+8.11%5/15/2025CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid LebowitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$45.00 ➝ $56.00+18.63%4/17/2025Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingD. ArchilaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingMarket Outperform2/12/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph CatanzaroSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$37.00 ➝ $38.00+8.85%1/24/2025OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJay OlsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$41.00 ➝ $33.00-3.31%12/23/2024Brookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingL. CannSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy12/20/2024BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingE. DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$36.00 ➝ $40.00+18.76%10/21/2024TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$27.00 ➝ $34.00+18.55%12/19/2023BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageBuy$27.00+15.68%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:43 AM ET. EXEL Forecast - Frequently Asked Questions What is Exelixis' forecast for 2025? According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Exelixis is $44.42, with a high forecast of $60.00 and a low forecast of $33.00. Should I buy or sell Exelixis stock right now? 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 9 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXEL shares. Does Exelixis's stock price have much upside? According to analysts, Exelixis's stock has a predicted upside of 13.17% based on their 12-month stock forecasts. Has Exelixis been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Exelixis's stock had 1 upgrade and 1 downgrade by analysts. What analysts cover Exelixis? Exelixis has been rated by research analysts at Barclays, Guggenheim, HC Wainwright, JMP Securities, Morgan Stanley, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, William Blair, and Zacks Research in the past 90 days. Do Wall Street analysts like Exelixis more than its competitors? Analysts like Exelixis more than other "medical" companies. The consensus rating for Exelixis is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EXEL compares to other companies. Stock Forecasts and Research Tools Related Companies BIIB Stock Forecast UTHR Stock Forecast INCY Stock Forecast NBIX Stock Forecast EXAS Stock Forecast IONS Stock Forecast BMRN Stock Forecast MDGL Stock Forecast RGEN Stock Forecast HALO Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:EXEL) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
